LUPIN Lupin Q3 FY25 results (Oct–Dec 2024) and concall
Management summary
- Lupin reported a strong Q3 FY25 with robust revenue growth of 10.6% YoY to ₹5,619 crores and a significant EBITDA margin expansion to 24.3%, the highest in five years.
- The US business achieved a five-year high in revenues, and India formulations outpaced market growth.
- The company maintained strong regulatory compliance and continued to invest heavily in R&D, focusing on complex generics and specialty assets.
- Navigating challenges like muted respiratory growth in India and currency impacts in Emerging Markets..
Source: Inve concall analysis and management guidance record.
Highlights
-
Reported strong performance across key markets with sequential and YoY growth, achieving the highest EBITDA margins in 5 years at 24.3%, up 420bps YoY.
-
US business delivered strong QoQ and YoY growth with revenues at a five-year high of USD 235 million, a 10.5% YoY increase.
-
India business grew by 11.9% YoY, with the India Formulation business recording 9.1% growth for 9M FY25 against an IPM growth of 8.2%.
-
Successfully filed Ranibizumab in EU and received EIR from USFDA for Pithampur Unit-1 with VAI classification, indicating strong regulatory compliance.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 4,208 |
| EBITDA | 1,411 |
| Net profit | 985 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Margin
EBITDA Margin Margin · FY25 · High confidence 23-23.5%
Revenue
US Business Growth Revenue · FY25 · High confidence double digit growth
Previously high single digit growth → double digit growth
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Timelines for key limited competition product launches in US Direct
So we are making progress on both applications with the agency and would expect that hopefully, approval sooner rather than later. But I think it'll be safe to assume that Tolvaptan would be the major contributor in the first half of the fiscal year and the injectables should ram
Clarifies the expected launch timelines and contribution phasing for key growth drivers like Tolvaptan and injectables.
Asked by Kunal Dhamesha, Macquarie
Slow growth in India's respiratory therapy segment Partial
I mean the market seems to be that way. I mean sequentially the number is as an absolute number up actually for respiratory, but it's been lagging for a while versus the rest of the market. Even for nine months, the market was only at 4%. We were at 3% for nine months and I mean
Highlights a specific underperforming segment in the India business and management's view on market trends, indicating a potential drag on overall India growth.
Asked by Kunal Dhamesha, Macquarie
Unlock risks & concerns, Q4 FY25 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 8 risks, concerns & management red flags
- 5 watchlist triggers for Q4 FY25
- +7 more guidance targets & verbatim management quotes
- +5 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





